159 Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers

• Lin Kang,
• Xiaokui Zhang,
• Robert Hariri,
• Xuan Guo,
• Tanel Mahlakõiv,
• Shuyang He,
• Hemlata Rana,
• Andrea DiFiglia,
• John Fitzgerald,
• Irene Raitman,
• Valentina Rousseva,
• Salvatore Rotondo

Affiliations

Lin Kang

4 Department of Gerontology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Xiaokui Zhang

Celularity Inc, Florham Park, New Jersey, USA

Robert Hariri

Celularity Inc, Florham Park, New Jersey, USA

Xuan Guo

Celularity Inc, Florham Park, New Jersey, USA

Tanel Mahlakõiv

Celularity Inc, Florham Park, New Jersey, USA

Shuyang He

Celularity Inc, Florham Park, New Jersey, USA

Hemlata Rana

Celularity Inc, Florham Park, New Jersey, USA

Andrea DiFiglia

Celularity Inc, Florham Park, New Jersey, USA

John Fitzgerald

5Medicine/Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA

Irene Raitman

Celularity, Florham Park, NJ, USA

Valentina Rousseva

Celularity, Florham Park, NJ, USA

Salvatore Rotondo

Celularity, Florham Park, NJ, USA